Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart Failure
Effects of a Transitional Care Program on Depression, Self-Efficacy, and Self-Care in Patients With Heart Failure: A Randomized Controlled Trial
Studieoversigt
Status
Intervention / Behandling
Detaljeret beskrivelse
Heart failure is a chronic condition associated with frequent hospitalizations, poor self-care behaviors, psychological distress, and reduced quality of life. Patients with heart failure often experience depression and inadequate self-management after hospital discharge, which may negatively affect treatment adherence and clinical outcomes.
Transitional care programs have been developed to improve continuity of care and support patients during the transition from hospital to home. Structured transitional care interventions may enhance patients' self-efficacy and self-care abilities while reducing depressive symptoms.
This randomized controlled trial aims to evaluate the effects of a structured transitional care program on depression, self-efficacy, and self-care behaviors in patients with heart failure. Eligible participants will be randomly assigned to either the intervention group or the usual care group. The intervention group will receive a structured transitional care program in addition to usual care, whereas the control group will receive usual care only.
Outcomes including depression, self-efficacy, and self-care behaviors will be measured before discharge and at 1 and 3 months after discharge using validated assessment instruments.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Taoyuan City
-
Guishan, Taoyuan City, Taiwan, 33305
- Chang Gung Memorial Hospital
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
Patients with a diagnosis of heart failure confirmed by a specialist physician. Patients with heart failure with reduced ejection fraction (HFrEF) and left ventricular ejection fraction (LVEF) ≤40%.
Age ≥20 years. Clear consciousness and no cognitive impairment. Ability to communicate in Mandarin, Taiwanese, or Hakka. Ability to complete the questionnaire independently or with assistance from the researcher.
Exclusion Criteria:
Patients who are unable to be discharged during the current hospitalization. Severe consciousness impairment, cognitive impairment, or severe mental illness affecting study participation.
Patients who are illiterate or unable to express themselves verbally. Patients who are bedridden long-term or unable to perform self-care activities. Patients who refuse to participate in the study. Patients who are already enrolled in a case management program.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Støttende pleje
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Transitional Care Program Group
Participants received a structured transitional care program including discharge education, telephone follow-up, and home care support for 3 months after discharge.
|
A structured transitional care program including discharge education, telephone follow-up, and home care support for 3 months after discharge.
|
|
Aktiv komparator: Usual Care Group
Participants received routine discharge education and standard follow-up care provided by the hospital after dischar
|
Participants received standard discharge routine care provided by the hospital after discharge.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Depression Score Measured by the Patient Health Questionnaire-9 (PHQ-9)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Depression will be assessed using the Patient Health Questionnaire-9 (PHQ-9).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
|
Change in Self-Efficacy Score Measured by the General Self-Efficacy Scale (GSES)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Self-efficacy will be assessed using the General Self-Efficacy Scale (GSES).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
|
Change in Self-Care Behavior Score Measured by the Self-Care of Heart Failure Index (SCHFI)
Tidsramme: Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Self-care behaviors will be assessed using the Self-Care of Heart Failure Index (SCHFI).
|
Baseline (before discharge), 1 month after discharge, and 3 months after discharge.
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 202300968B0
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Overgangspleje
-
Xuzhou Medical UniversityIkke rekrutterer endnuIkke-invasiv CAR-T-celleovervågning | BCMA-målrettet PET-skanning | CAR-T-cellebiodistribution og -persistens | GMP-overensstemmende Radiopharmaka-præparation
-
The Affiliated Hospital of Xuzhou Medical UniversityRekrutteringCLL | SLL | CAR-T celleterapiKina
-
Duke UniversityNational Institutes of Health (NIH)RekrutteringHæmatopoietisk stamcelletransplantation | CAR-T celleterapiForenede Stater
-
Patrick C. Johnson, MDRekruttering
-
Stiftung Swiss Tumor InstituteKlinik Hirslanden, Zurich; Palleos Healthcare GmbHRekrutteringPatientrapporterede resultatmål | CAR T-celleterapiSchweiz
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaRekrutteringCAR-T Terapi KomplikationerItalien
-
University Health Network, TorontoRekrutteringLymfom, der modtager CAR-T-terapiCanada
-
The Lymphoma Academic Research OrganisationBristol-Myers Squibb; Novartis; Gilead SciencesRekrutteringHæmatopatologi kvalificeret eller CAR-t-cellebehandlingFrankrig
-
Associació per a la Recerca Oncologica, SpainUkendtUrothelium Transitional Cell CarcinomSpanien, Holland
-
Henan Cancer HospitalFundamenta Therapeutics, Ltd.Ikke rekrutterer endnuAllogen, CAR-T, proteinsekvestrering, ikke-genredigeretKina
Kliniske forsøg med Structured Transitional Care Program
-
Chulalongkorn UniversityQueen Sirikit National Institute of Child Health (QSNICH), ThailandAfsluttetSund og rask | Præterm nyfødt | Neonatal intensiv afdelingThailand
-
The Hong Kong Polytechnic UniversityAfsluttet
-
University of Maryland, BaltimoreUniversity of Maryland Medical SystemTrukket tilbageHjertefejl | Lungebetændelse | Forhøjet blodtryk | Lungesygdom, kronisk obstruktiv | Patient Genindlæggelse | Diabetes mellitus dårlig kontrolForenede Stater
-
Peking UniversityCARsgen Therapeutics Co., Ltd.AfsluttetAvanceret solid tumorKina
-
National Cancer Institute (NCI)RekrutteringAkut lymfatisk leukæmi | Lymfoblastisk lymfom | Leukæmi, lymfatisk, kronisk, B-celle | Lille lymfatisk lymfom | Leukæmi, akut lymfatisk | B-celle kronisk lymfatisk leukæmi | B-lymfocytisk leukæmi, kroniskForenede Stater
-
Mehrdad Abedi, MDNational Cancer Institute (NCI)RekrutteringTilbagevendende diffust stort B-cellet lymfom | Refraktært diffust stort B-cellet lymfomForenede Stater